Phathom Pharmaceuticals appoints James Topper, M.D., Ph.D. to Board of Directors

Phathom Pharmaceuticals, Inc.

James Topper appointed as Class III director effective September 22, 2022; will serve on nominating and corporate governance committee.
Topper previously served on board from January 2018 to May 2021; currently Managing General Partner at Frazier Life Sciences.
Granted option to purchase 20,000 shares vesting over three years; cash compensation per Non-Employee Director Compensation Program.
Board determined Topper meets Nasdaq independence requirements; no related person transactions.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

James Topper, M.D., Ph.D.

Class III Director

PHAT · Phathom Pharmaceuticals, Inc.

Effective: 2022-09-22
Filed: September 26, 2022, 7:59 PM ET

On September 22, 2022, the board of directors (the “Board”) of Phathom Pharmaceuticals, Inc. (the “Company”) appointed James Topper, M.D., Ph.D. to the Board as a Class III director, effective immediately, with an initial term expiring at the 2025 annual meeting of stockholders of the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

James Topper, M.D., Ph.D. was appointed as Class III Director at Phathom Pharmaceuticals, Inc..

Action: appointed
Role: Class III Director

Exact text from the filing

On September 22, 2022, the board of directors (the “Board”) of Phathom Pharmaceuticals, Inc. (the “Company”) appointed James Topper, M.D., Ph.D. to the Board as a Class III director, effective immediately, with an initial term expiring at the 2025 annual meeting of stockholders of the Company.

View on SEC.gov

Phathom Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-250665

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.